LTW Technologies has received 5 FDA clearances for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.

“LTW is the clear leader in LED-based treatment therapies. This step in LTW Technologies' evolution further proves that LTW and the LIGHTWAVE DELUXE series set the industry standard. No other device on the market can match up to the LIGHTWAVE system.” Michael Poling, President, LTW Technologies.

The LIGHTWAVE DELUXE series is the first and only FDA cleared device of its kind. The DELUXE series is the first LED light therapy system to combine red, infrared and blue in one unit, obtain clearances for each wavelength separately, and receive clearances for multi-wavelengths treatments for use on the face and body.

The following indications are now added to the existing uses for the LIGHTWAVE DELUXE SERIES:

• Red light for use in dermatology for treatment of superficial, benign vascular and pigmented lesions.
• Red and Blue light for emitting energy in the Red and Blue region of the spectrum to treat dermatological conditions, specifically mild to moderate acne vulgaris.
• Blue light for dermatological conditions and moderate inflammatory acne vulgaris.
• Red and Infrared light for emitting energy in the Red and Infrared region of the spectrum for the treatment of periorbital wrinkles.
• Infrared light for emitting energy in the Infrared spectrum to provide topical heating to elevate tissue temperature; for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.

LTW Technologies is evaluating other indications for the LIGHTWAVE system with plans on seeking clearance in the near future. Additionally, a “home use” or “over the counter” version of the LIGHTWAVE system is in the final developmental stages and plans are being made to enter the market in 2010.